on INNATE PHARMA (EPA:IPH)
Innate Pharma to Attend Jefferies Global Healthcare Conference
Innate Pharma SA, a biotechnology firm focused on cancer immunotherapies, announced its executive team's participation in the Jefferies Global Healthcare Conference from June 2–4, 2026, in New York. This participation involves direct meetings with investors, providing an opportunity to discuss their latest advances in antibody therapeutics.
Innate Pharma is known for developing cutting-edge treatments like IPH4502 for solid tumors and collaborative efforts with AstraZeneca on non-small cell lung cancer therapies. Their approach centers on unmet medical needs with a focus on innovative antibodies.
This engagement with investors highlights Innate's commitment to fostering relationships within the biotech community and advancing its strategic goals. Innate is publicly traded on Euronext Paris and Nasdaq, underlining its global reach and influence in the healthcare industry.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news